Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in participants with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.

Trial Details

NCT ID

NCT05316129

Phase

PHASE1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Follicle Stimulating Hormone Receptor T Cells

Locations (sample)

Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

Aged 18 years or older and able to provide informed consent.
Pathologically confirmed diagnosis of invasive (Grades 1-3) epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma (EOC)…
Have measurable disease or detectable (non-measurable) disease.
Consent to have tumor obtained for correlative study testing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →